Su Deng, PhD
Assistant ProfessorAbout
Research
Publications
2026
Game of clones: decipher lineage plasticity in hormone-driven cancers
Leonita A, Cheng S, Warrick J, Kim I, Deng S, Mu P. Game of clones: decipher lineage plasticity in hormone-driven cancers. Cellular And Molecular Life Sciences 2026, 83: 236. PMID: 42014520, PMCID: PMC13237331, DOI: 10.1007/s00018-026-06171-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
ATHENA: A deep learning-based AI for functional prediction of genomic mutations and synergistic vulnerabilities in prostate cancer.
Cheng S, Jin X, Qian J, Jiang Y, Kim IY, Deng S, Mu P. ATHENA: A deep learning-based AI for functional prediction of genomic mutations and synergistic vulnerabilities in prostate cancer. BioRxiv 2025 PMID: 41357974, DOI: 10.1101/2025.11.26.690813.Peer-Reviewed Original ResearchNotch as a Driver of Lineage Plasticity and Therapeutic Target in Enzalutamide-Resistant Prostate Cancer.
Jiang Y, Cheng S, Li L, Fraidenburg M, Kim IY, Deng S, Mu P. Notch as a Driver of Lineage Plasticity and Therapeutic Target in Enzalutamide-Resistant Prostate Cancer. BioRxiv 2025 PMID: 40501767, DOI: 10.1101/2025.05.26.656166.Peer-Reviewed Original ResearchPan-cancer Analysis Identified Ectopic RUNX1T1 Associated with Lineage Plasticity.
Jiang Y, Cheng S, Kim IY, Deng S, Mu P. Pan-cancer Analysis Identified Ectopic RUNX1T1 Associated with Lineage Plasticity. BioRxiv 2025 PMID: 40488132, DOI: 10.1101/2025.04.18.649575.Peer-Reviewed Original ResearchAndrogen Deprivation-Induced TET2 Activation Fuels Prostate Cancer Progression via Epigenetic Priming and Slow-Cycling Cancer Cells.
Li L, Cheng S, Xu Y, Deng S, Mu P, Yu X. Androgen Deprivation-Induced TET2 Activation Fuels Prostate Cancer Progression via Epigenetic Priming and Slow-Cycling Cancer Cells. BioRxiv 2025 PMID: 40196510, DOI: 10.1101/2025.03.26.645495.Peer-Reviewed Original Research
2024
Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1
Rodarte K, Heyman S, Guo L, Flores L, Savage T, Villarreal J, Deng S, Xu L, Shah R, Oliver T, Johnson J. Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1. Cancer Research 2024, 84: 3522-3537. PMID: 39264686, PMCID: PMC11534540, DOI: 10.1158/0008-5472.can-24-1388.Peer-Reviewed Original ResearchHyd/UBR5 defines a tumor suppressor pathway that links Polycomb repressive complex to regulated protein degradation in tissue growth control and tumorigenesis
Wen P, Lei H, Deng H, Deng S, Tirado C, Wang M, Mu P, Zheng Y, Pan D. Hyd/UBR5 defines a tumor suppressor pathway that links Polycomb repressive complex to regulated protein degradation in tissue growth control and tumorigenesis. Genes & Development 2024, 38: 675-691. PMID: 39137945, PMCID: PMC11368183, DOI: 10.1101/gad.351856.124.Peer-Reviewed Original ResearchZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson N, Li X, Li X, Metang L, Mukherji A, Xu Q, Tirado C, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y, Zhu H, Hanker A, Raj G, Zhu G, He H, Wang Z, Arteaga C, Liang H, Feng F, Wang Y, Wang T, Mu P. ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer Discovery 2024, 14: 1496-1521. PMID: 38591846, PMCID: PMC11285331, DOI: 10.1158/2159-8290.cd-23-0539.Peer-Reviewed Original Research
2023
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance
Rodriguez Tirado C, Wang C, Li X, Deng S, Gonzalez J, Johnson N, Xu Y, Metang L, Sundar Rajan M, Yang Y, Yin Y, Hofstad M, Raj G, Zhang S, Lemoff A, He W, Fan J, Wang Y, Wang T, Mu P. UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. Oncogene 2023, 43: 265-280. PMID: 38030789, PMCID: PMC10798893, DOI: 10.1038/s41388-023-02890-5.Peer-Reviewed Original ResearchZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
Xu Y, Wang Z, Sjöström M, Deng S, Wang C, Johnson NA, Gonzalez J, Li X, Metang LA, Tirado CR, Mukherji A, Wainwright G, Yu X, Yang Y, Barnes S, Hofstad M, Zhu H, Hanker A, He HH, Chen Y, Wang Z, Raj G, Arteaga C, Feng F, Wang Y, Wang T, Mu P. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. BioRxiv 2023 PMID: 37961351, DOI: 10.1101/2023.10.24.563645.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Teaching & Mentoring
Mentoring
Madeline Foster
Postgrad associate2026 - PresentAnfeng Luo
Postdoc2025 - PresentJiaying Qian
Postdoc2025 - Present
News & Links
Media
Genomic Mutations, Treatment-Resistance & Prostate Cancer - The Deng Lab at Yale School of Medicine
The Deng Lab focuses on understanding and overcoming therapy resistance in advanced prostate cancer. By integrating functional genomics, metabolomics, and tumor modeling, the lab investigates how alterations at the transcriptional and translational levels drive lineage plasticity and metabolic rewiring that enable tumors to evade androgen receptor–targeted therapies. Through these studies, the Deng Lab seeks to identify key molecular vulnerabilities and translate mechanistic insights into novel therapeutic strategies for lethal prostate cancer.